Abstract: Gene therapy has been successfully used in several areas of medicine as a technique to either alter defective genes or as method to enable delivery of therapeutic proteins. Despite advances in surgical and pharmaceutical interventions for diseases of bone regeneration and healing, results in certain patient groups remain sub-optimal. With this consideration, gene therapy is currently being investigated as a means of facilitating healing and improving outcomes. Two broad techniques which are currently utilised by research teams are discussed in this review; ex vivo and in vivo. The underlying principle is similar in each case; the use of gene therapy to alter target cells to deliver proteins which facilitate bone regeneration. However, whereas ex vivo techniques involve performing genetic manipulations outside the body and then introducing the altered cells to the desired site, in vivo techniques execute genetic manipulations inside the body by the introduction of vectors directly to the desired location. Results from small animal models for both techniques are promising, however, further research is required to demonstrate both safety and efficacy prior to any future clinical application.
INTRODUCTION
Despite significant advances in our understanding of bone biology, outcomes from the treatment of many orthopaedic disorders remain suboptimal. Gene therapy is an approach which shows promise in the treatment and perhaps cure for many disorders of bone which are refractory to current therapy [1, 2] .
It appears self-evident that gene therapy may be used to directly modify defective genes in host DNA, especially in the case of genetic diseases such as osteogenesis imperfecta. However, another application of gene therapy is as a delivery method of therapeutic proteins in non-genetic disorders such as fracture non-union or bone defects [2] . Indeed the majority of research into gene therapy for bone disorders utilises this strategy. Although there have been successful outcomes from gene therapy trials in other areas such as cancer treatment [3] , arthritis [4] , and Parkinson's disease [5] , there are no reported clinical trials of gene therapy in disorders of bone.
This review will briefly outline the various techniques for gene delivery to bone, and will discuss current research on gene therapy for bone regeneration.
Methods of Gene Delivery to Bone
The transfer of genetic material (transgene) to a target cell is not necessarily a straightforward process. Whilst out *Address correspondence to this author at the Clinical Research Fellow, Bristol Royal Infirmary, Upper Maudlin St, Bristol, BS2 8HW, UK; Tel: 01179230000; Fax: 01173424206; E-mail: Tarassoli@mail2web.com side the cell, DNA is subject to enzymatic degradation in addition to uptake by non-targeted cells [1] . Following this it must cross the cell membrane, a difficult task considering its high molecular weight and anionic nature. Furthermore, once inside the cell, it may undergo lysosomal and cytoplasmic degradation to varying degrees [6] . To overcome these obstacles and ensure adequate levels of transgene delivery, a vector is required [2] . Vectors are broadly categorised as viral or non-viral.
The first experiments with gene therapy involved the introduction of "naked" DNA to cells by physical methods or non-viral vectors, a technique known as transfection. However, the biochemical efficiency of transfection is low, and hence viral-based vectors were developed to improve on this. The transfer of DNA by viral vectors is known as transduction. Viral vectors used for gene therapy are created by using replication-deficient viruses which are altered to have the disease-causing sequences removed and instead replaced with therapeutic ones [6] . Depending on the requirements of therapy, a choice of either DNA-based or RNA-based viral vectors is available. Examples of commonly used RNAbased viruses include retrovirus or lentivirus, whilst DNAbased ones include adenovirus and adeno-associated virus (AAV) [6] . Each have their advantages and disadvantages, but the main distinction between the two is that RNA-based viral vectors are capable of long-term transgene expression through gene integration with the host cells genome, unlike DNA-based vectors which do not integrate [7, 8] . Viral vectors have been used with great success in gene therapy, although they do have several notable drawbacks [6] , such as the limit of the molecular size of DNA that can be cloned into the viral vector [6, 9] . However, perhaps the most prominent drawback are concerns regarding safety, in particular following the death of a subject in one clinical pilot study [10] , and the development of T-cell leukemic disease in one quarter of the subjects in another trial [11] .
When compared with viral vectors, non-viral vectors have lower production costs, can be used to carry larger nucleic acids, and they are widely regarded as a safer technique. However, their effectiveness in vivo is significantly inferior due to their transient and relatively muted transgene expression [12] . First developed in the 1970s, non-viral vectors are natural (liposome-based) or synthetic (polymerbased) compounds which facilitate the introduction of genetic material into cells [12, 13] . Their functional characteristic is their cationic nature which enables them to traverse the cell membrane [14] . Despite their relatively low efficacy non-viral vectors have been successfully employed in clinical trials for the treatment of cancer [15, 16] , cystic fibrosis [17] and ocular degenerative diseases [1] .
Physical methods of gene delivery work on the principle of using force to overcome the membrane barrier of cells and allow transfection. Techniques include simple needle injection or the generation of pores in the cell membrane using ultrasound or electric current [1, 18] , and there have been numerous studies reporting the successful implementation of these methods in bone formation [19] [20] [21] [22] . These techniques are also commonly used in conjunction with vectors to improve their efficacy [1] .
There exist two general strategies for the transfer of vectors to bone. The first is in vivo (or direct) delivery in which gene delivery via a vector to target cells takes place inside of the body. The second is ex vivo (or cell-based) delivery, whereby gene delivery to harvested stem cells takes place outside of the body, after which the modified cells are introduced to the body by intravenous injection or local implantation [2] . These two strategies are summarised in Fig. (1) and described briefly below.
There are three approaches for in vivo delivery of transgenes: (i) systemic delivery; (ii) direct local injection; and (iii) Gene activated matrices (GAMs). Although an attractive prospect, systemic delivery, particularly of viral vectors, is a complex and perhaps dangerous process, therefore it has only been used in an ex vivo manner with systemic administration of therapeutic gene products [2, 18] . Direct injection of transgenes is a simpler method, and may appear the obvious choice for bony lesions, however, despite local infiltration there are still varying degrees of spread within tissues which may lead to inadvertent ossification of surrounding muscles, ligaments and cartilage [18] . GAMs are threedimensional biomaterials which act as a platform for vectors introduced to a localised area and are useful for avoiding unintended spread of transfection to local tissues [23] .
Even though results from the in vivo strategies listed above have been promising, nevertheless concerns regarding the safety of introducing vectors directly to the body has motivated research into ex vivo techniques. Autologous cells used for the ex vivo gene delivery are frequently mesenchymal stem cells (MSCs) harvested from either marrow [24] , muscle [25] or adipose tissue [26] attached to scaffolds [27] . Although effective, ex vivo culture can be expensive and time-consuming. Moreover, harvesting MSCs subject the patient to an additional painful procedure. Therefore more recent strategies utilising autologous cells have involved the use "expedited" techniques [2] , which allow harvest and implantation within the same operative procedure [28] [29] [30] .
Gene Therapy in Bone Regeneration
Although gene therapy has prospects for application in a wide range of bone disorders such as osteogenesis imperfecta and osteoporosis, the vast majority of the literature reports on experiments on bone healing [2] . Achieving union following fracture in particular patient groups or in criticalsized bone loss as a result of tumour resection, infection or severe traumatic injuries can be difficult and results are generally poor [31] [32] [33] [34] . Current clinical therapies to tackle nonunion involve the use of growth factors such as bone morphogenic proteins (BMPs) to stimulate bone formation [35] and the use of bone grafts to fill critical-sized defects [36] .
Options for bone grafting are either autologous iliac crest bone graft (ICBG) or allografts from human cadavers. ICBG is the current gold standard, and although its use does not carry the risk of disease transmission as with cadaver allograft [37] , it does however have a significant risk of complications relating to the donor site which include pain, deep infection and nerve damage [38] [39] [40] . Furthermore, harvested quantities may not be sufficient to treat the required defect [40] .
BMPs are multi-functional growth factors which are members of the transforming growth factor (TGF) beta family [41] . Twenty have been isolated to date, of which several have the potential to induce bone formation [35, 42] . The commercial potential of BMPs was quickly realised following their discovery, and the relatively low yields that resulted from extraction from purified cadaver bones meant that recombinant gene techniques were soon employed to produce the desired quantities of BMPs [43] . There are presently two commercially available BMPs: Infuse ® rhBMP-2 (Medtronic) and OP-1 ® rhBMP-7 (Stryker). Whilst results from studies on spinal fusion have been encouraging, long bone defects to do not appear to be as responsive to rhBMPs [35, 44, 45] . Furthermore, to compensate their short biological half-lives, high concentrations are often required locally to achieve effective bone regeneration. This increase costs sub- stantially, and recently there is mounting evidence that there are significant previously unreported adverse side-effects with the use of such high doses [44, 45] .
Considering the above limitations, gene therapy has been used as an alternative strategy for both in vivo and ex vivo to facilitate the local delivery of growth factors in suitable and sustained concentrations to treat fractures and defects.
In Vivo Techniques
As discussed previously, options for gene delivery to bone include viral and non-viral vectors. Table 1 summarises a selection of studies reporting on animals models using in vivo techniques of gene transfer.
Much of the in vivo literature reports on the use of BMP-2 to induce bone formation with generally good outcomes. However, a few studies have experimented with the use of other BMPs [46] [47] [48] [49] [50] [51] [52] and growth factors [53] [54] [55] [56] [57] [58] . In the only study to perform a methodical direct comparison, Ishihara et al. found that Ad.BMP-2 was superior to Ad.BMP-6 in accelerating callus formation and the restoration of biomechanical strength in equine metatarsal osteotomies [46] .
Adenoviruses have been used extensively in the literature as a vector to deliver therapeutic proteins to bone defects in vivo. This is in part due to a relatively simpler manufacturing process (in comparison to retroviruses) which enables its production in high quantities. Musgrave et al. were the first to demonstrate the potential of adenoviruses with an in vivo technique to induce bone formation [68] . In a murine model they demonstrated the ability of the vector to induce significant quantities of ossification in the triceps surae. Of note, however, was the superior level of bone formation in the immune-deficient group when compared to the immunocompetent group. This is not surprising, though, considering that a known disadvantage of using adenoviruses in vivo is their tendency to incite inflammatory and immune mediated responses in the host organism which can lead to destruction of the transduced cells [2, 72] . This has potential implications for treatments requiring repeat or prolonged dosing regimens. Furthermore, the inflammatory response, if uncontrolled, can be potentially lethal. Indeed, the most publicised death of a patient in a gene therapy trial was as a result systemic inflammatory response syndrome (SIRS) following systemic administration of adenovirus-5 [10] .
Nevertheless, the results obtained in Musgrave's study may be only be an indication of adenovirus activity in muscle. Indeed, in a separate study, Betz et al. found that Ad.BMP-2 (adenoviral BMP-2) was able to stimulate bone formation in an immunocompetent rat bone defect, but were not able to replicate those results with intramuscular injection of the same vector in similar animals [63] .
With regards to the timing of adenoviral administration, some studies have elected for a delayed (7-10 days) injection as this has been shown to improve bone formation in osseous defects [64] . A possible reason for this is that delayed injection coincides with the maximal expression of an adenoviral receptor on osteoclasts [73] . This is a logical explanation considering that a study of rhBMP-2 timing using direct injection of the protein found that the optimal time was actually at the time of surgery or shortly after [74] .
Retroviruses do not provoke the same immune response as do adenoviruses, however they are more difficult to produce and carry the risk of insertional mutagenesis [6] . Charles Rundle's team in California are the only group which have used retroviruses for in vivo based gene therapy in bone [47, 55, 56] . Experimenting first with a BMP-2/4 hybrid gene, they were unable to show a significant difference between control and treated fractures in terms of time to union [47] . However, they found no evidence of viral vector infection of extraskeletal tissues, which is useful for determination of the safety of the vector in vivo. Following on from this study, they were able to show promising results from the use of cyclooxygenase-2 (COX-2) [56] and LIM mineralization protein-1 (LMP-1) [55] . When compared by the authors to BMP 2/4, they noted that LMP-1 improved bony union without causing heterotopic ossification [55] .
The most common method for delivering the vectors in situ is by direct injection. However, this has the potential to lead to dispersion of the vector outside of the desired area. Several studies have implemented the use of "scaffolds" for the delivery of vectors in situ [23] . One example of this is a construct known as a gene-activated matrix (GAM) which is impregnated with the vector of choice and following implantation releases the vector in a more accurate and controlled manner than direct injection to the surrounding tissues. This technique has been used with plasmid based vectors [53, 71] and adenoviral vectors [54] , both demonstrating good bone healing without dispersion sometimes seen with direct injection. In a slightly different approach, one group has used adenoviral BMP-2 coated allograft as the scaffold for vector delivery [70] . Using a mouse femoral defect model, they found that although bone formation did not appear to be significantly different when compared to the live allograft group, there was a significant biomechanical advantage, with the coated allograft group displaying the torsional rigidity equivalent to an unfractured femur. Additionally, the coated allografts were found to contain live bone marrow which suggests that they are not susceptible to the formation of micro-cracks, which is commonly a cause of failure with live allografts. Another major advantage is that the manufacturing process produces aseptic allografts which do carry the potential for disease transmission as do live allografts [37] .
Physical methods such as electroporation and sonoporation have also been used with plasmids or "naked" DNA as a potentially safer alternative to viral vectors, however results show that with current methods they lack the transfection efficiency of viral vectors or scaffold constructs [1, 2, 36] .
Ex vivo Techniques
Owing to the perceived relative safety of performing genetic manipulations outside of the body, and the negation of host immune response against viral vectors, ex vivo techniques have been used more frequently than in vivo techniques in studies of gene therapy for bone regeneration. Ex vivo techniques involve introducing cells to the body after they have undergone genetic manipulations outside the body, often attached to scaffolds [27, 75, 76] . Studies in the litera-ture vary based on their choice of vector, cell and technique. Table 2 shows a list of studies using ex vivo methods.
The choice of site used for the harvest of cells for transduction remains a contentious issue. Bone marrow stromal cells have been commonly used for cultures by many investigators. These cells demonstrate high transduction efficiency with adenoviral vectors, and readily secrete BMP after implantation, which are both ideal characteristics. Furthermore, the secreted BMP positively affects the cells themselves, by means of an "autocrine" mechanism which induces differentiation into osteoblasts. This essentially provides two mechanisms by which they may promote bone formation. Bone marrow stromal cells are not the only progenitors to display this activity in vivo, and similar observations have been made for muscle [86] , adipose [26, 83, 98] and periosteum [77] . The contribution of the autocrine effect has been questioned by Gugala and colleagues, however, who found no difference in the osteoinductive properties of human bone marrow derived stem cells when compared to skin fibroblasts and diploid fetal lung cell lines [99] . Harvesting bone marrow cells in a clinical setting can be painful for the patient, and reserves are relatively limited. For this reason, there is much interest in the use of adipose tissue to derive stem cells for gene therapy. Obtaining these cells is by means of liposuction aspirates, which can be carried out under local anaesthetic at multiple sites on the body. Furthermore, yields are much higher than that of bone marrow [98] , resulting in an effectively limitless supply.
The relatively disappointing results obtained by some investigators with adenoviral gene cell based strategies, in particular with spinal fusion models [83] , and the finding of persistent immune responses in long bone experiments involving larger animals [91] have prompted others to experiment with retroviral gene delivery. Miyazaki and colleagues, using rat bone marrow stromal in a spinal fusion model, compared the efficacy of adenoviral BMP-2 and lentiviral BMP-2 transduced cells [100] . While spines in both groups demonstrated adequate fusion, the lentiviral group demonstrated superior thickness and quality of fusion mass, even with extension into adjacent levels where no fusion bed was surgically prepared. Furthermore, they found that immunocompetent mice when treated with the adenoviral cell based strategy had inferior bone quality of fusion when compared to immunocompromised mice treated when with the same cells. These findings support the results from a study by Feeley who used a CCD (cooled-charged-coupled device) camera to observe the duration of transgene expression in adenoviral and lentiviral bone formation models [101] . They found that although lentivirus resulted in expression of both luciferase and BMP-2 at therapeutic levels for over 3 months, adenovirus only sustained this level for 21 days. In a similar study, Virk reiterated the duration of adenoviral transgene expression as being less than 3 weeks, but also carried out mechanical testing and demonstrated higher energy of failure with bone from lentiviral gene transfer when compared to adenoviral [102] . Results from these studies suggest that prolonged transgene expression is desirable for bone formation, and more so in situations such as larger defects or in cases of spinal fusion. However, prolonged expression of BMP-2 may have a possible oncogenic effect [100] , and in addition to the risk of insertional mutagenesis and oncogenic activation from retroviral integration [103] , may mean that their use in a clinical setting would be unsuitable.
Cell based gene delivery via expanded culture is the standard technique for ex vivo studies in the literature. However, it does have certain drawbacks, namely the time and expense required to produce cultures of transduced cells. This practice subjects the patient to two operative procedures on separate days. More recent techniques involve harvesting, transducing and reimplanting therapeutic cells within the same procedure. These "expedited" or "same-day" methods have shown promising results when used with cells derived from marrow [29] , muscle and fat [104] and even peripheral blood [30] . Another approach which can allow for "same day" gene therapy is to use pre-prepared allografted cells, however, results from their use in animal models has been mixed [105, 106] .
As with direct strategies for gene delivery, some studies have adopted a cell-based non-viral approach [93] [94] [95] [96] [97] . In all cases, bone formation has been evident but not to the same extent as that seen with viral cell based strategies. Park and colleagues performed a direct comparison of adenoviral and liposome vectors found that for the treatment of a rat femoral defect with BMP-2, the adenoviral vector group achieved complete bone healing in 4 weeks whereas the liposome vector group achieved the same result in 6 weeks [107] . However they concluded that as there was adequate bone healing in both cases, the best vector may be the liposome based as they do not suffer from many of the disadvantages of viral based strategies, but instead are easier to prepare and can carry larger volumes of DNA.
Furthermore, in a novel bone model Sheyn and colleagues were able to show that BMP-6 delivered to a vertebral defect by nucleofection™ (an enhanced form of electroporation -Lonza AG) of a plasmid vector was able to close the defect by 12 weeks [97] . This has implications not only for the further use of this non-viral technology but also for the potential use of BMPs to treat osteoporotic fractures in this manner.
CONCLUSION
It is clear from the summarised evidence that gene therapy for bone regeneration holds promise for eventual clinical application. Results from in vivo and ex vivo techniques show that both are potentially suitable candidates.
Ishihara and colleagues are one of the only investigators to have performed a direct comparison of the two techniques [108] . They found that BMP-2 secreting skin fibroblasts were more effective at promoting formation than direct injection of a BMP-2 adenoviral vector. A possible reason for this, as has been discussed, is the ability of certain cell lines to undergo differentiation into osteocytes and contribute to bone formation.
Although proponents of each technique cite their unique advantages, ultimately the most important factor in gene therapy is safety. In this regard, ex vivo techniques are undoubtedly safer as all genetic modifications are carried out extrinsic to the body and the introduction of any modified cells can be screened as part of an added security to prevent inadvertent implantation of cancerous cells.
Nevertheless, much of the current data for both techniques is on small animal models, in particular rodents. Indeed, there are very few studies investigating gene therapy for bone healing in larger animals. Certainly, prior to the establishment of human trials it is necessary to have a larger base of evidence to demonstrate both efficacy and safety in animals more closely related to humans.
The successful application of gene therapy in bone healing would greatly improve outcome from both complex fractures with significant bone loss, and potentially bone weakened through age related demineralisation. Furthermore, its application may also be significant in specific bones which have undergone osteonecrosis though an ischaemic insult [58, 89, 90] .
